TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19839212

Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions (surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pragmatic studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multicentre clinical studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Good clinical and comparative health care effectiveness research
Number of subjects: 0
Study: 22269571

Group type: EXPERIMENTAL
Intervention: PRIME For Life(®) ‐ PFL
Number of subjects: 522

Group type: COMPARATOR
Intervention: Intervention as usual (IAU)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Both interventions (PFL and IAU)
Number of subjects: 522
Study: 15955039

Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EBP) performed on day 2
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EBP) performed on day 3
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Epidural blood patch (EBP) performed on day 4
Number of subjects: 79
Study: 12601664

Group type: EXPERIMENTAL
Intervention: Hand splinting in the functional position (10 degrees - 30 degrees wrist extension) for a maximum of 12 hours each night for 4 weeks.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Routine therapy-motor training for upper-limb use and upper-limb stretches (5 days a week).
Number of subjects: 28
Study: 9447855

Group type: EXPERIMENTAL
Intervention: Aprotinin (1.106 KIU bolus followed by 5 x 10(5) KIU/h infusion)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 7560990

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccines
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30000
Study: 2757771

Group type: EXPERIMENTAL
Intervention: Intensive psychosensorial stimulation at home by mothers, trained and inspected by nurses.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no intensive psychosensorial stimulation).
Number of subjects: 96
Study: 589308

Group type: EXPERIMENTAL
Intervention: Busulphan
Number of subjects: 243

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 11978259

Group type: EXPERIMENTAL
Intervention: Whole grain oat-based cereals
Number of subjects: 88

Group type: COMPARATOR
Intervention: Refined grain wheat-based cereals
Number of subjects: 88
Study: 31957965

Group type: EXPERIMENTAL
Intervention: Extended dual antiplatelet therapy (DAPT) beyond 12 months
Number of subjects: 4197

Group type: COMPARATOR
Intervention: Control group (standard DAPT for 12 months)
Number of subjects: 4197

Group type: EXPERIMENTAL
Intervention: Extended DAPT
Number of subjects: 4197
Study: 30020983

Group type: EXPERIMENTAL
Intervention: ABM training (attending away from pain)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham training (no training direction)
Number of subjects: 58
Study: 26492058

Group type: EXPERIMENTAL
Intervention: Intraoperative Steroid Administration
Number of subjects: 549

Group type: COMPARATOR
Intervention: Non-recipients (Control)
Number of subjects: 549
Study: 24486732

Group type: EXPERIMENTAL
Intervention: Consumer-directed e-health strategy for cardiovascular risk management
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2000
Study: 22665903

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg/d orally
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 19650804

Group type: COMPARATOR
Intervention: Ropivacaine 13 mg
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ropivacaine 10 mg plus sufentanil 5 microg
Number of subjects: 64
Study: 19095139

Group type: EXPERIMENTAL
Intervention: Statins plus ezetimibe
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (target LDL-C <= 100 mg/dl)
Number of subjects: 0
Study: 15741225

Group type: EXPERIMENTAL
Intervention: Gemcitabine-docetaxel (GD)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Cisplatin-vinorelbine (CV)
Number of subjects: 311
Study: 12032392

Group type: COMPARATOR
Intervention: abciximab
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: loading dose clopidogrel (450 mg)
Number of subjects: 39

Group type: COMPARATOR
Intervention: ticlopidine post-stenting
Number of subjects: 39

Group type: COMPARATOR
Intervention: aspirin + ticlopidine post-stenting
Number of subjects: 39

Group type: COMPARATOR
Intervention: aspirin + abciximab + ticlopidine post-stenting
Number of subjects: 39
Study: 10073848

Group type: EXPERIMENTAL
Intervention: Revascularization after first acute myocardial infarction
Number of subjects: 817

Group type: COMPARATOR
Intervention: Conservative treatment (no revascularization)
Number of subjects: 817
Study: 7888514

Group type: EXPERIMENTAL
Intervention: Thiopentone (4-6 mg.kg‐1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Propofol (2-2.5 mg.kg‐1)
Number of subjects: 36
Study: 2671808

Group type: EXPERIMENTAL
Intervention: Flunoxaprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzydamine
Number of subjects: 0
Study: 96062

Group type: EXPERIMENTAL
Intervention: Neutron-telecobalt therapy
Number of subjects: 265

Group type: COMPARATOR
Intervention: Telecobalt therapy
Number of subjects: 265
Study: 31242350

Group type: EXPERIMENTAL
Intervention: Workplace injuries in micro and small enterprises (MSE)
Number of subjects: 290
Study: 28456395

Group type: EXPERIMENTAL
Intervention: Lipid-depleting filter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (without lipid-depleting filter)
Number of subjects: 30
Study: 25410653

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 83
Study: 23142194

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21050694

Group type: EXPERIMENTAL
Intervention: Group-based multi-professional educational programme
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group receiving information according to hospital routines
Number of subjects: 128
Study: 19496838

Group type: EXPERIMENTAL
Intervention: Topical gluco-oligosaccharide and collagen tripeptide F
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16446331

Group type: EXPERIMENTAL
Intervention: Estrogen Replacement Therapy (ERT)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1236
Study: 14505916

Group type: EXPERIMENTAL
Intervention: Botulinum F toxoid vaccine (Bot F) administered 1-3 times
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Botulinum F toxoid vaccine (Bot F) administered 3 times over 28-42 days
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Booster dose of Botulinum F toxoid vaccine (Bot F) administered at 1 year
Number of subjects: 144

Group type: COMPARATOR
Intervention: Licensed, alum-adsorbed hepatitis B vaccine (Engerix-B)
Number of subjects: 144
Study: 10806283

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive function (fourth measure with greatest processing load)
Number of subjects: 0
Study: 8632929

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (4 mL, 2 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (4 mL of 0.9% saline solution)
Number of subjects: 50
Study: 1483494

Group type: EXPERIMENTAL
Intervention: +/- Nicardipine 50 mg b.d.
Number of subjects: 19

Group type: COMPARATOR
Intervention: Slow release nifedipine 20 mg b.d.
Number of subjects: 19
Study: 2416663

Group type: EXPERIMENTAL
Intervention: Cholecystokinin (0.5; 1.0 or 1.3 IDU X kg‐1 X h‐1) plus secretin (0.5 CU X kg‐1 X h‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cholecystokinin (0; 0.5; 1.0 or 1.3 IDU X kg‐1 X h‐1) plus secretin (0.5 CU X kg‐1 X h‐1)
Number of subjects: 20
Study: 31508899

Group type: EXPERIMENTAL
Intervention: Imipenem/relebactam 500/250 mg administered as a 30-minute intravenous infusion four times daily.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renal function estimated by creatinine clearance.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weight and health status.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simulations for joint target attainment.
Number of subjects: 0
Study: 29215518

Group type: EXPERIMENTAL
Intervention: Low-Molecular-Weight Heparin + Aspirin
Number of subjects: 185

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 185
Study: 26956476

Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation (ACI)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Arthroscopic debridement (AD)
Number of subjects: 82
Study: 24657003

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy plus trastuzumab
Number of subjects: 235

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Pathological complete response with trastuzumab
Number of subjects: 235

Group type: COMPARATOR
Intervention: Pathological complete response with chemotherapy alone
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Cardiovascular adverse events
Number of subjects: 235
Study: 22907422

Group type: EXPERIMENTAL
Intervention: DFMO + sulindac
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 20814327

Group type: EXPERIMENTAL
Intervention: Full adherence (204 patients, 33.7%)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Nonadherence (287 patients, 47.4%)
Number of subjects: 605

Group type: EXPERIMENTAL
Intervention: Persistent medication refusal (114 patients, 18.8%)
Number of subjects: 605
Study: 18004659

Group type: EXPERIMENTAL
Intervention: Culturally sensitive school-based preventive intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less acculturated families
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spanish-language families with less acculturated adolescents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family language and target child's familism values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Family single- vs. dual-parent status and primary parent's work hours
Number of subjects: 0
Study: 16087788

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg per day administered on awakening
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg per day administered at bedtime
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg per day administered at bedtime in non-dipper patients
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg per day administered at bedtime in dipper patients
Number of subjects: 257
Study: 12118869

Group type: EXPERIMENTAL
Intervention: Surfaces with large pixel-to-pixel luminance variations
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vertical line patterns
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vertical stimuli
Number of subjects: 8
Study: 10383561

Group type: EXPERIMENTAL
Intervention: Microencapsulated aspirin 162.5 mg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Aspirin EC 150 mg
Number of subjects: 104

Group type: COMPARATOR
Intervention: Aspirin EC 75 mg
Number of subjects: 104
Study: 8533996

Group type: EXPERIMENTAL
Intervention: melphalan-prednisone and interferon
Number of subjects: 583

Group type: COMPARATOR
Intervention: melphalan-prednisone
Number of subjects: 583
Study: 1858154

Group type: EXPERIMENTAL
Intervention: CsA monotherapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Triple-drug therapy
Number of subjects: 151
Study: 6342657

Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no ECV)
Number of subjects: 30
Study: 29474093

Group type: EXPERIMENTAL
Intervention: Foot reflexology
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (no reflexology)
Number of subjects: 154
Study: 29145839

Group type: EXPERIMENTAL
Intervention: TG-C (intraarticular 3:1 mixture of non-transduced allogeneic human chondrocytes and TG-C)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: TG-C
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 26575258

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir for 12 weeks (HCV genotype 2)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Sofosbuvir-ribavirin for 12 weeks (HCV genotype 2)
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir for 12 weeks (HCV genotype 3)
Number of subjects: 543

Group type: COMPARATOR
Intervention: Sofosbuvir-ribavirin for 24 weeks (HCV genotype 3)
Number of subjects: 543
Study: 24125107

Group type: EXPERIMENTAL
Intervention: Erythropoietin alfa
Number of subjects: 56
Study: 21930046

Group type: EXPERIMENTAL
Intervention: epi‐LASIK flap-on
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: epi‐LASIK flap-off
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LASEK flap-on
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: LASEK flap-off
Number of subjects: 40

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 40
Study: 18760142

Group type: EXPERIMENTAL
Intervention: Early invasive strategy (PCI with stents)
Number of subjects: 1235

Group type: COMPARATOR
Intervention: Ischemia-guided management
Number of subjects: 1235
Study: 16997664

Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg daily)
Number of subjects: 5269

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5269
Study: 15638069

Group type: EXPERIMENTAL
Intervention: Ginkgo special extract EGb 761
Number of subjects: 0
Study: 10860192

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (diastolic blood pressure goal of 75 mmHg)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Moderate blood pressure control (diastolic blood pressure goal of 80‐89 mmHg)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Intensive therapy (nisoldipine or enalapril)
Number of subjects: 470

Group type: COMPARATOR
Intervention: Moderate therapy (nisoldipine or enalapril)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 470

Group type: COMPARATOR
Intervention: Moderate blood pressure control
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 470

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 470
Study: 9217378

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 mg administered 2 hours before operation (group S)
Number of subjects: 10

Group type: COMPARATOR
Intervention: No pre-treatment (group C)
Number of subjects: 10
Study: 8380242

Group type: EXPERIMENTAL
Intervention: Ganciclovir
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 3542493

Group type: EXPERIMENTAL
Intervention: Ethamsylate
Number of subjects: 33
Study: 3403101

Group type: EXPERIMENTAL
Intervention: L-carnitine (1-g doses twice daily for 45 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29402258

Group type: EXPERIMENTAL
Intervention: Home-based play-assisted stimulation for 1 hour during weekly home visits over 6 months
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Home-based play-assisted stimulation
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (basic services only)
Number of subjects: 78
Study: 27305924

Group type: EXPERIMENTAL
Intervention: 240 J dose of near-infrared (NIR) light therapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham dose
Number of subjects: 9
Study: 25914281

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 28
Study: 23837606

Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic treatment (GDHT)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Routine fluid treatment
Number of subjects: 460
Study: 20946674

Group type: EXPERIMENTAL
Intervention: Tutoring by physicians with content expertise (n = 5)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Tutoring by physicians with process expertise (n = 3)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Tutoring by a combination of content experts for 11 sessions and process experts for 10 sessions (n = 3)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Process experts (overall rating from students)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Content experts
Number of subjects: 151
Study: 18257904

Group type: EXPERIMENTAL
Intervention: Ribavirin treatment
Number of subjects: 175

Group type: COMPARATOR
Intervention: Non-ribavirin treatment (Control B)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control A (previously healthy subjects)
Number of subjects: 175
Study: 16414295

Group type: EXPERIMENTAL
Intervention: Alfentanil (25ng/ml and 75ng/ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine (0.14mg/kg and 0.28mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14717279

Group type: EXPERIMENTAL
Intervention: Astigmatic refractive correction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 11511130

Group type: EXPERIMENTAL
Intervention: Exposure to misleading postevent information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral and leading postevent information
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retention intervals of 1 day and 6 weeks
Number of subjects: 0
Study: 9300118

Group type: EXPERIMENTAL
Intervention: Topical budesonide during active treatment periods in children with asthma (aged 12-16 years)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Conventional method for calculation of growth rates
Number of subjects: 36

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 36
Study: 8337162

Group type: EXPERIMENTAL
Intervention: Intravenous lorazepam (Ativan)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous prochlorperazine (Compazine)
Number of subjects: 24
Study: 3095557

Group type: EXPERIMENTAL
Intervention: Enteral feeding via needle catheter jejunostomy (N.C.J.) with an elemental diet (Vivonex HN) starting at 18 hours and advanced to 3,000 ml/day (3,000 kcal, 20 gm N2) within 72 hours.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (no supplemental nutrition during first 5 days).
Number of subjects: 75
Study: 30232858

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (30 min, once daily, 6 times a week for 30 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Donepezil hydrochloride (5 mg/night for 30 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Donepezil hydrochloride
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 27532525

Group type: EXPERIMENTAL
Intervention: Fluconazole (two doses of 300mg given 1 week apart)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Fluconazole (two doses of 300mg given 1 week apart) + Ketoconazole shampoo (one application)
Number of subjects: 71
Study: 24418570

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied bilaterally to the quadriceps muscles, n = 11, 8 weeks, 5 days/week, twice/day, 45 min/session
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group, n = 9
Number of subjects: 20
Study: 22955004

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Xeno III) with resin composite (Tetric Ceram)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Xeno III) with poly-acid modified resin composite (Dyract AP)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Xeno III) with continuous curing technique
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Xeno III) with soft start curing technique
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system (Xeno III) with pulse delay curing technique
Number of subjects: 139
Study: 20300024

Group type: EXPERIMENTAL
Intervention: Fatigued session (after Wingate anaerobic protocol)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonfatigued session
Number of subjects: 15
Study: 18397984

Group type: EXPERIMENTAL
Intervention: Berberine (1.0 g daily)
Number of subjects: 116
Study: 16231254

Group type: EXPERIMENTAL
Intervention: Real-time PCR for respiratory viruses and atypical pathogens
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Real-time PCR results reported to treating physician
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Real-time PCR
Number of subjects: 107

Group type: COMPARATOR
Intervention: Conventional diagnostic tests
Number of subjects: 107
Study: 12005274

Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg
Number of subjects: 635

Group type: COMPARATOR
Intervention: Frovatriptan (0.5, 1, 2.5, or 5 mg)
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: Frovatriptan (all doses)
Number of subjects: 635
Study: 10701818

Group type: EXPERIMENTAL
Intervention: Individualized counseling sessions
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: Home visits/discussion groups
Number of subjects: 1367

Group type: EXPERIMENTAL
Intervention: Computerized appointment-tracking system
Number of subjects: 1367

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1367
Study: 9347681

Group type: EXPERIMENTAL
Intervention: Fish oil (1800 mg of eicosapentanoic acid [EPA] + 1200 mg of docosahexanoic acid) with garlic powder (1200 mg) capsules daily for 1 month
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 40
Study: 8516490

Group type: EXPERIMENTAL
Intervention: Nitrendipine (calcium antagonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study: 3758388

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (IUI)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Intracervical insemination (ICI)
Number of subjects: 49
Study: 31216247

Group type: EXPERIMENTAL
Intervention: Resealed restorations
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control restorations
Number of subjects: 152